CN114652791A - New use of ginseng root-strengthening oral liquid for preventing or treating sicca syndrome - Google Patents

New use of ginseng root-strengthening oral liquid for preventing or treating sicca syndrome Download PDF

Info

Publication number
CN114652791A
CN114652791A CN202210346928.XA CN202210346928A CN114652791A CN 114652791 A CN114652791 A CN 114652791A CN 202210346928 A CN202210346928 A CN 202210346928A CN 114652791 A CN114652791 A CN 114652791A
Authority
CN
China
Prior art keywords
syndrome
parts
oral liquid
root
new use
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN202210346928.XA
Other languages
Chinese (zh)
Inventor
孙成磊
程国良
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong New Time Pharmaceutical Co Ltd
Original Assignee
Shandong New Time Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong New Time Pharmaceutical Co Ltd filed Critical Shandong New Time Pharmaceutical Co Ltd
Publication of CN114652791A publication Critical patent/CN114652791A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/076—Poria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/40—Cornaceae (Dogwood family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A61K36/804—Rehmannia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/884—Alismataceae (Water-plantain family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/894—Dioscoreaceae (Yam family)
    • A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8965—Asparagus, e.g. garden asparagus or asparagus fern
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8968—Ophiopogon (Lilyturf)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Abstract

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a new application of ginseng root-strengthening oral liquid in preventing or treating sicca syndrome. The ginseng root-strengthening oral liquid is a unique variety of Lunan Qianpu pharmaceutical Limited company, and has the efficacies of nourishing yin and supplementing qi, strengthening the root and reinforcing primordial qi, clearing away heat and cooling blood, promoting blood circulation to remove blood stasis, nourishing yin and promoting the production of body fluid, nourishing yin and moistening dryness, tonifying liver and kidney and the like. Experiments prove that the pharmaceutical composition can obviously improve the salivary secretion of a model rat, improve T lymphocyte subpopulations in peripheral blood of a mouse and reduce the level of immunoglobulin in serum, and can be used for preparing medicines for treating or preventing sjogren syndrome.

Description

New use of ginseng root-strengthening oral liquid for preventing or treating sicca syndrome
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a new application of ginseng root-strengthening oral liquid in preventing or treating sicca syndrome.
Background
The sjogren's syndrome is a chronic autoimmune disease mainly invading exocrine glands such as lacrimal gland and salivary gland, also called as autoimmune exocrine gland body disease, and has high morbidity, which is mostly seen in women over 40 years old. The pathological mechanism is mainly that a large number of lymphocytes and plasma cells of exocrine glands are infiltrated due to the excessive response reaction of autoimmunity, so that the cells of the glands are damaged and the functions of the glands are lost, thereby a series of clinical symptoms and manifestations are presented, including keratoxerosis, conjunctivitis, xerostomia, hyposalivation, parotid swelling, chest distress, abdominal distension, soreness and weakness of waist, insomnia, night sweat and the like.
Sicca syndrome is an autoimmune disease with complex etiology and pathogenesis, and modern medicine considers that the pathogenesis of sicca syndrome is immune abnormality of an organism under the invasion of multiple pathogenic factors such as heredity, virus infection and the like, such as T4/T8 lymphocyte subpopulation and abnormal ratio, hyperglycoglobinemia and the like. Western medicine has no effective method for treating sicca syndrome, can only relieve symptoms through hormones, immunosuppressants and the like, has large side effect, is easy to relapse after stopping administration, is easy to mask the state of an illness, and delays the optimal treatment time.
The sicca syndrome belongs to the category of dryness syndrome in traditional Chinese medicine. The causes of sicca syndrome are mainly the following: inherent deficiency: the disease is mainly caused by congenital deficiency and yin essence loss; or deficiency of body fluid due to yin deficiency; or over-strain due to prolonged illness can lead to yin and fluid deficiency, failing to nourish the eyes and eyes, leading to this disease. Women use yang for yin, and women over 40 years old gradually run out of their sex, essence and blood are deficient, yin and fluid are deficient, and fluid is consumed due to yin deficiency and internal heat, which results in mouth and eye clear and malnutrition, and meridian qi and blood obstruction, which causes the disease. Second, acquired factors: or emotional damage and overstrain; or malnutrition due to long-term illness and consumption of essence and blood; or the annual sex will be exhausted; or treating with wrong treatment, such as sweating, vomiting, and descending; or taking pungent and warm-rising powder; or blood and essence loss, which can lead to deficiency of yin fluid and loss of healthy qi, and this disease is caused. ③ six excesses: in the six excesses, wind, summer-heat, dryness and fire are called yang pathogens, and yang heat hyperactivity can burn body fluid; wind-cold can transform into heat, wind-heat can transform into dryness, heat consumes fluid, and dryness can transform into fluid. The initial stage of the disease is in the meridian table. Obstruction of collaterals and vessels causes pain of joints and muscles, and dryness of body fluids causes dry mouth and eyes. Long-term invasion of the interior will damage the internal organs. The traditional Chinese medicine carries out syndrome differentiation treatment according to sicca syndrome caused by different reasons and by combining clinical practice, and the syndrome differentiation treatment is divided into the following steps: dryness affecting lung type, damp-heat accumulation type, dryness-heat blood-forcing type, qi and blood stasis type, yin deficiency internal heat type, liver and kidney yin deficiency type, and qi and yin deficiency type.
The ginseng root-strengthening oral liquid has the effects of nourishing yin, tonifying qi, strengthening body resistance and cultivating vigor. Can be used for treating deficiency of yin, asthenia, cough, palpitation, short breath, hectic fever, soreness of waist, tinnitus, and dry stool. At present, no report about the application of ginseng root-strengthening oral liquid in preventing or treating sicca syndrome exists.
Disclosure of Invention
The invention provides a new application of ginseng root-strengthening oral liquid in preventing or treating sicca syndrome. The ginseng root-strengthening oral liquid has the effects of nourishing yin and tonifying qi, strengthening the root and consolidating vitality, clearing heat and cooling blood, activating blood and dissolving stasis, nourishing yin and promoting the production of body fluid, nourishing yin and moistening dryness, tonifying liver and kidney and the like, and can effectively prevent or improve the sicca syndrome.
The ginseng root strengthening oral liquid comprises ginseng, rehmannia root, prepared rehmannia root, dogwood, Chinese yam, tree peony bark, oriental waterplantain rhizome, tuckahoe, asparagus and dwarf lilyturf tuber, and has new application in preventing or treating sicca syndrome.
The ginseng root-strengthening oral liquid comprises 10-60 parts of ginseng, 30-100 parts of rehmannia root, 40-90 parts of prepared rehmannia root, 30-80 parts of dogwood, 50-130 parts of Chinese yam, 50-80 parts of moutan bark, 30-90 parts of rhizoma alismatis, 30-120 parts of poria cocos, 50-90 parts of radix asparagi and 60-120 parts of radix ophiopogonis.
Preferably, the ginseng root-strengthening oral liquid comprises 30-50 parts of ginseng, 50-80 parts of rehmannia root, 40-60 parts of prepared rehmannia root, 50-70 parts of dogwood, 70-100 parts of Chinese yam, 50-80 parts of moutan bark, 45-60 parts of oriental waterplantain rhizome, 50-90 parts of poria cocos, 60-75 parts of asparagus and 60-90 parts of radix ophiopogonis.
Preferably, the ginseng root-strengthening oral liquid can also be prepared into a clinically acceptable dosage form by adding other pharmaceutically acceptable active ingredients and auxiliary materials through a conventional process, and is used for preventing or treating sicca syndrome.
Further preferably, the dosage form is decoction, electuary, tablet, capsule, granule, pill or powder.
The sjogren's syndrome is primary sjogren's syndrome.
The traditional Chinese medicine syndrome differentiation of the sicca syndrome belongs to one of dryness-evil attacking lung type, damp-heat accumulation type, dryness-heat blood-forced type, qi and blood stasis type, yin deficiency and internal heat type, liver and kidney yin deficiency type and qi and yin deficiency type.
Preferably, the sicca syndrome is one of damp-heat accumulation type and qi and blood stasis type according to traditional Chinese medicine syndrome differentiation.
The clinical symptoms of sicca syndrome include but are not limited to keratoconjunctivitis sicca, xerostomia, hyposalivation, parotid swelling, chest distress, abdominal distension, soreness and weakness of waist, insomnia and night sweat.
Ginseng is sweet, slightly bitter and warm. It enters spleen, lung, heart and kidney meridians. Tonify primordial qi, recover pulse to stop collapse, tonify spleen and lung, promote the production of body fluid and nourish blood, induce tranquilization and promote intelligence. Can be used for treating asthenia, collapse, cold limbs, weak pulse, spleen deficiency, anorexia, lung deficiency, cough, asthma, body fluid deficiency, thirst, internal heat, diabetes, deficiency of both qi and blood, asthenia, palpitation, insomnia, sexual impotence, and cold womb.
Rehmannia root, radix rehmanniae, sweet and cold. It enters heart, liver and kidney meridians. Clearing away heat and cooling blood, nourishing yin and promoting the production of body fluid. Can be used for treating heat entering nutrient-blood, epidemic febrile disease, macula, hematemesis, epistaxis, yin injury due to fever, crimson tongue, polydipsia, constipation due to body fluid consumption, fever due to yin deficiency, bone steaming, fatigue, internal heat, and diabetes.
Prepared rehmannia root, radix rehmanniae Preparata, sweet and slightly warm. To nourish yin, enrich blood, replenish essence and replenish marrow. Can be used for treating deficiency of liver-yin and kidney-yin, soreness of waist and knees, hectic fever, night sweat, nocturnal emission, internal heat, diabetes, blood deficiency, sallow complexion, cardiopalmus, severe palpitation, menoxenia, metrorrhagia, metrostaxis, hemorrhage, giddiness, tinnitus, and early white beard and hair.
Dogwood, sour, astringent and slightly warm. It enters liver and kidney meridians. Tonify liver and kidney, astringe and induce depletion. Can be used for treating vertigo, tinnitus, soreness of waist and knees, sexual impotence, spermatorrhea, enuresis, frequent micturition, metrorrhagia, leukorrhagia, sweating, asthenia, internal heat, and diabetes.
Yam, sweet and neutral. It enters spleen, lung and kidney meridians. Tonify spleen and stomach, promote the production of body fluid and nourish lung, tonify kidney and astringe essence. Can be used for treating spleen deficiency, anorexia, chronic diarrhea, lung deficiency, cough, asthma, spermatorrhea, leukorrhagia, frequent micturition, and diabetes due to deficiency heat. The bran-parched rhizoma Dioscoreae has effects of invigorating spleen and invigorating stomach. Can be used for treating spleen deficiency, anorexia, diarrhea, loose stool, and leukorrhagia.
Mu Dan Pi is bitter, pungent and slightly cold. It enters heart, liver and kidney meridians. Clear heat and cool blood, activate blood and resolve stasis. Can be used for treating fever, nutritional blood, epidemic heat, speckle, hematemesis, nocturnal fever, early coolness, no sweat, hectic fever, dysmenorrhea, traumatic injury, carbuncle, swelling, and sore.
Ze Xie is sweet, bland and cold in nature. It enters kidney and bladder meridians. Induce diuresis and drain dampness, purge heat, resolve turbidity and reduce blood fat. Can be used for treating dysuria, edema, abdominal distention, diarrhea, oliguria, phlegm retention, vertigo, pyretic stranguria, pain, and hyperlipidemia.
Poria cocos, sweet, bland and neutral. It enters heart, lung, spleen and kidney meridians. Induce diuresis and drain dampness, invigorate spleen and calm heart. Can be used for treating edema, oliguria, phlegm and fluid retention, dizziness, palpitation, spleen deficiency, anorexia, loose stool, diarrhea, uneasiness, palpitation, and insomnia.
Tian Dong, sweet, bitter and cold. It enters lung and kidney meridians. Nourish yin and moisten dryness, and promote the secretion of body fluid from the lung. Can be used for treating dry cough due to lung dryness, cough with sticky phlegm, soreness of waist and knees, hectic fever due to yin-deficiency, internal heat, thirst, dry throat, and constipation due to intestinal dryness.
Mai Dong is sweet, slightly bitter and slightly cold. It enters heart, lung and stomach meridians. Nourish yin, promote the production of body fluid, moisten lung and clear away heart-fire. Can be used for treating lung dryness, dry cough, yin deficiency, tuberculosis, sore throat, body fluid consumption, thirst, internal heat, vexation, insomnia, and constipation.
The invention has the beneficial effects that:
the invention provides a new application of ginseng root-strengthening oral liquid in preventing or treating sicca syndrome; the ginseng root-strengthening oral liquid has the effects of nourishing yin, tonifying qi, strengthening the root, cultivating vigor, clearing heat, cooling blood, promoting blood circulation to remove blood stasis, nourishing yin, promoting the production of body fluid, nourishing yin, moistening dryness, tonifying liver and kidney and the like by mutual matching and mutual cooperation. The test proves that the compound can obviously improve the salivary secretion of a model rat, improve T lymphocyte subpopulation in peripheral blood of the rat, reduce the levels of immunoglobulin IgG and TNF-alpha in serum, inhibit hyperfunction of humoral immunity and regulate immune balance, and can be used for treating or preventing sjogren syndrome.
Detailed Description
The invention is further illustrated by the following examples. It should be properly understood that: the examples of the present invention are intended to be illustrative only and not to be limiting, and therefore, the present invention is intended to be simply modified within the scope of the present invention as claimed.
Animal experiments
Establishing a sjogren syndrome SD rat model, and observing the influence of the ginseng root consolidating oral liquid on the saliva quantity, peripheral blood T lymphocyte subpopulations and serum IgG and TNF-alpha of the sjogren syndrome SD rat model. T lymphocytes are an important immunocompetent cell, CD4+Cells and CD8+The cells are two subsets of T lymphocytes with different functions, and respectively play positive and negative regulation roles in immune response to form a T cell network, CD4+/CD8+The ratio represents the overall immune balance; IgG antibody plays a role in activating complement and neutralizing various toxins in immune response, and IgG of a patient with Sjogren syndrome is high, which indicates the existence of hyperimmunoasmia, and is a manifestation of systemic involvement of Sjogren syndrome; TNF-alpha is a cytokine with various biological activities, can participate in the pathogenesis of various autoimmune diseases, has an important role in maintaining the immune balance in vivo, and the level of TNF-alpha is in positive correlation with the disease condition of Sjogren syndrome.
1. Experimental reagent and medicine
Ginseng root-strengthening oral liquid, 10ml x 14 pieces, national standard character Z10940013, lunan pachu pharmaceuticals limited;
prednisone acetate tablets, 5mg x 100 tablets, the Chinese medicine standard character H33021207, Zhejiang Xianju pharmaceutical Co., Ltd;
diphtheria-pertussis-tetanus vaccine, 5.0 ml/vaccine, national drug standard S10820008, Chengdu biological product institute;
freund's complete adjuvant, sigma company.
2. Test object
SD rats, SPF grade, male, 120, body weight 200 + -20 g; 6-week-old SD rats, SPF grade, male, 5; the source is as follows: the experimental animal breeding company of Jinanpunyue produces license number SCXK (Shandong) 20190003. All rats were housed strictly according to the environmental standards for laboratory animals as set forth by the national ministry of laboratory animal administration.
3. Experimental methods
Anesthetizing 5 SD rats of 6 weeks old, picking bilateral submaxillary glands under an aseptic condition, removing submaxillary gland envelopes and connective tissues, washing the submaxillary gland envelopes and connective tissues for 3 times by using normal saline, combining obtained submaxillary gland samples, shearing the submaxillary gland samples, weighing the submaxillary gland samples, adding 0.1mol/L phosphate buffer solution with pH7.2, adding 80mL of phosphate buffer solution into each gram of submaxillary gland samples, homogenizing the submaxillary gland samples under an ice bath condition, centrifuging the submaxillary gland samples for 30min at 4000 rpm at 4 ℃, taking 60mL of supernate, adding an isovolumetric Freund complete adjuvant, fully mixing the supernate and emulsifying the mixture to obtain an emulsified protein antigen. And freezing the residual supernatant for later use. And (5) freezing and storing the emulsified protein antigen for later use.
120 rats weighing 200 ± 20g were randomly divided into 4 groups: a model group, a control group, a ginseng root-strengthening oral liquid high-dose group and a ginseng root-strengthening oral liquid low-dose group, wherein each group comprises 30 ginseng root-strengthening oral liquid high-dose groups; each rat was injected subcutaneously with emulsified protein antigen in the toes and groin of both hind feet, 1mL each. The day of the first injection of the emulsified protein antigen was taken as day 1. The emulsified protein antigens were injected again on days 21 and 35, and each emulsified protein antigen was injected subcutaneously into the toes and groin of both hind feet, each in an amount of 1 mL. On days 1, 7, 21 and 35, each rat was injected with crevas albuginea vaccine subcutaneously in the back, and each rat was injected subcutaneously with 0.2 mL. 2 mice in the model group are sacrificed at the 50 th day after the model building, and the submaxillary gland of the model mouse discovers characteristic pathological changes of sicca syndrome such as lymphocyte infiltration, gland atrophy and the like through pathological morphology observation, which indicates that the model building is successful.
Each group of rats is respectively administered by intragastric administration for 1 time a day, wherein the ginseng root-strengthening oral liquid high-dose group comprises: 4 mL/kg; the ginseng root strengthening oral liquid low dose group comprises: 2 mL/kg; control group: prednisone acetate tablets, 2 mg/kg; model group: and (5) irrigating stomach normal saline.
Salivary secretion amount: continuously gavage for 30 days, taking out the dry cotton ball after last administration for 12h, placing under the tongue of the rat for 10 min, and taking out. Saliva secretion (mg) is the wet weight of cotton balls-dry weight of cotton balls.
T lymphocyte subpopulation: continuously perfusing the stomach for 30 days, taking blood from the abdominal aorta of the rat 12h after the last administration, collecting the blood in a heparin anticoagulation tube, and detecting by using an EPICS XL flow cytometer.
Serum IgG, TNF- α: continuously perfusing the stomach for 30 days, taking blood from the rat orbit after 12h of the last administration, collecting serum, and detecting by a double-antibody sandwich ABC-ELISA method.
4. Results of the experiment
The results are shown in tables 1, 2 and 3.
TABLE 1 salivary secretion of rats
Group of n Salivary quantity (mg)
Model set 28 32.55±1.92
Control group 30 36.08±2.17*
Ginseng root-strengthening oral liquid high-dose group 30 41.35±2.26**△△
Ginseng root strengthening oral liquid low dose group 30 37.18±1.80**
Note: significant difference (P < 0.05) and very significant difference (P < 0.01) compared to the model group; compared with the control group, the compound of the formula,△has significant difference (P is less than 0.05),△△with very significant difference (P <)0.01)。
Compared with the saliva secretion amount of a model group, the ginseng root-strengthening oral liquid has very significant difference in both high and low dose groups, and has significant difference in a control group; compared with the saliva secretion amount of a control group, the ginseng root-strengthening oral liquid has very significant difference in the high-dose group. The ginseng root-strengthening oral liquid can obviously improve the salivary secretion of a model rat.
TABLE 2 rat peripheral blood T lymphocyte subpopulations
Group of n CD4+(％) CD8+(％) CD4+/CD8+
Model set 28 43.55±5.12 15.63±4.85 2.62±0.18
Control group 30 39.18±7.57 17.42±1.48△ 2.29±0.32*
Ginseng root-strengthening oral liquid high dose group 30 34.70±5.92* 18.07±2.26△ 1.96±0.55*
Ginseng root strengthening oral liquid low dose group 30 40.36±6.35 17.29±1.79 2.34±0.21*
Note: significant difference (P < 0.05) and very significant difference (P < 0.01) compared to the model group; compared with the control group, the compound had better effect,△has significant difference (P is less than 0.05),△△has very significant difference (P < 0.01).
As shown in Table 2, the ginseng root-strengthening oral liquid and the prednisone acetate both can improve the T lymphocyte subpopulation in the peripheral blood of mice and regulate the immune function, and compared with the model group, the oral liquid has the advantages that the CD4 is CD4+/CD8+With significant differences.
TABLE 3 immunological indices of rat sera
Group of n IgG concentration (mg/ml) TNF-alpha concentration (pg/ml)
Model set 28 27.35±2.70 44.27±6.80
Control group 30 18.90±4.75* 36.41±4.59*
Ginseng root-strengthening oral liquid high dose group 30 18.16±6.02* 31.08±4.19**△
Ginseng root-strengthening oral liquid low dose group 30 20.42±5.26* 34.60±7.34*
Note: significant differences (P < 0.05) and very significant differences (P < 0.01) compared to the model group; compared with the control group, the compound of the formula,△has significant difference (P is less than 0.05),△△has very significant difference (P < 0.01).
As can be seen from Table 3, after administration for 30 days, the IgG concentration in the serum of the rat is obviously reduced, and compared with the model group, the significant difference is provided, which indicates that the ginseng root-strengthening oral liquid can reduce the serum immunoglobulin level in the rat model, correct the hyperglobulin blood syndrome and inhibit the hyperfunction of humoral immunity; after 30 days of administration, the concentration of TNF-alpha in the high-dose group of the ginseng root-strengthening oral liquid is obviously reduced compared with that in the model group, and has obvious difference, compared with the control group, the ginseng root-strengthening oral liquid has obvious difference, which shows that the ginseng root-strengthening oral liquid can reduce the level of serum TNF-alpha in a rat model and maintain immune balance.

Claims (8)

1. The ginseng root strengthening oral liquid comprises ginseng, rehmannia root, prepared rehmannia root, dogwood, Chinese yam, tree peony bark, oriental waterplantain rhizome, tuckahoe, asparagus and dwarf lilyturf tuber, and has new application in preventing or treating sicca syndrome.
2. The new use as claimed in claim 1, wherein the ginseng root-strengthening oral liquid comprises 10-60 parts of ginseng, 30-100 parts of rehmannia root, 40-90 parts of prepared rehmannia root, 30-80 parts of cornus officinalis, 50-130 parts of Chinese yam, 50-80 parts of moutan bark, 30-90 parts of alisma orientale, 30-120 parts of poria cocos, 50-90 parts of asparagus and 60-120 parts of ophiopogon root.
3. The new use as claimed in claim 1, wherein the ginseng root-securing oral liquid can be prepared into a clinically acceptable dosage form for preventing or treating sjogren syndrome by adding pharmaceutically acceptable other active ingredients and auxiliary materials through a conventional process.
4. The new use as claimed in claim 3, wherein the dosage form is decoction, granule, tablet, capsule, granule, pill or powder.
5. The new use as claimed in claim 1, wherein the sjogren's syndrome is primary sjogren's syndrome.
6. The new use as claimed in claim 1, wherein the sjogren's syndrome is one of dryness attacking lung type, damp-heat accumulation type, dryness-heat blood-forcing type, qi-blood stasis type, yin deficiency and internal heat type, liver and kidney yin deficiency type, and qi-yin deficiency type according to traditional Chinese medicine syndrome differentiation.
7. The new use as claimed in claim 6, wherein the sicca syndrome is one of damp-heat accumulation type and qi and blood stasis type according to traditional Chinese medicine syndrome differentiation.
8. The new use as claimed in claim 1, wherein the manifestations of clinical symptoms of sjogren's syndrome include but are not limited to keratoconjunctivitis sicca, xerostomia, hyposalivation, mumps bloating, chest tightness, abdominal distension, soreness and weakness in the loins, insomnia, night sweats, difficulty in urination, rough skin, dark-colored spots.
CN202210346928.XA 2021-04-09 2022-04-01 New use of ginseng root-strengthening oral liquid for preventing or treating sicca syndrome Withdrawn CN114652791A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2021103800117 2021-04-09
CN202110380011 2021-04-09

Publications (1)

Publication Number Publication Date
CN114652791A true CN114652791A (en) 2022-06-24

Family

ID=82033959

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210346928.XA Withdrawn CN114652791A (en) 2021-04-09 2022-04-01 New use of ginseng root-strengthening oral liquid for preventing or treating sicca syndrome

Country Status (1)

Country Link
CN (1) CN114652791A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116473017A (en) * 2023-03-22 2023-07-25 首都医科大学附属北京同仁医院 Modeling method of mouse model based on Sjogren syndrome induced by mouse lacrimal gland

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
冷南方: "《中国中成药优选》", 31 January 2014, 人民军医出版社 *
郭鹏举等: "《中国非处方药完全手册》", 31 May 2005, 陕西科学技术出版社 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116473017A (en) * 2023-03-22 2023-07-25 首都医科大学附属北京同仁医院 Modeling method of mouse model based on Sjogren syndrome induced by mouse lacrimal gland
CN116473017B (en) * 2023-03-22 2024-01-05 首都医科大学附属北京同仁医院 Modeling method of mouse model based on Sjogren syndrome induced by mouse lacrimal gland

Similar Documents

Publication Publication Date Title
CN110787233B (en) Liver-protecting traditional Chinese medicine composition, extract and pharmaceutical application thereof
CN104873624B (en) A kind of pharmaceutical composition for gouty arthritis
CN105456897A (en) Traditional Chinese medicine composition containing argy wormwood leaf for treating spleen deficiency gasterasthenia type chronic gastritis
CN114652791A (en) New use of ginseng root-strengthening oral liquid for preventing or treating sicca syndrome
CN113713039A (en) Traditional Chinese medicine composition for treating membranous nephropathy and application thereof
CN103055285A (en) Traditional Chinese medicine for treating forepart hepetocirrhosis and preparation method thereof
CN101549073B (en) Medicament for treating idiopathic edema and preparation method thereof
CN108392611A (en) It is a kind of to treat the immune traditional Chinese herbal decoction and preparation method thereof of canker sore raising
CN101647816A (en) Bionic enzymatic hydrolysate for animal skins and application thereof
CN102940808A (en) Prescription medicine for treating lung cancer and preparation method
CN104042895A (en) Traditional Chinese medicine composition for treating systemic lupus erythematosus and use thereof
CN101129763A (en) Chinese patent medicine for treating post partum hypogalactia
CN103142943B (en) Traditional Chinese medicine composite with immune function and used for treating mastitis of cows
CN105920316A (en) Traditional Chinese medicine preparation with functions of improving immunity of dairy cows and preventing mastitis of dairy cows
CN106166262A (en) A kind of Chinese medicine composition treating chronic renal failure
CN112138126A (en) Composition for effectively relieving dysmenorrhea and preparation method thereof
CN111084878A (en) Biological medicine and medical total nutrient food for lung and respiratory system diseases and preparation method thereof
CN109646574A (en) A kind of Chinese medicine composition and preparation method thereof and Chinese materia medica preparation promoting postpartum recovery
CN104740428B (en) A kind of compound tonifying blood containing red skin of peanut pharmaceutical preparation and its application and detection method
CN104800729A (en) Decoction capable of nourishing kidney, promoting recovery, and eliminating albuminuria
CN103432335B (en) Medicament for treating chyluria and preparation method thereof
CN114869928B (en) Traditional Chinese medicine composition for treating cerebrovascular diseases and application thereof
CN102861192A (en) Medicine composition for chronic renal failure and peritoneal fibrosis
CN102512622B (en) Chinese medicine composition for treating stomachache of damp and hot accumulation sluggish
CN1088596C (en) Chinese medicine with immunosuppression fuction for treating immunosterility (immunoacyesis)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20220624